The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
New mRNA Vaccine Reduces Risk variation of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.